Newsroom

Sorted by: Latest

-

Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer

TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). The continuing research seeks to evaluate the efficacy and...
-

Submissions Now Open for the 2027 Phenom HR Awards

PHILADELPHIA--(BUSINESS WIRE)--Submissions Now Open for the 2027 Phenom HR Awards...
-

UBS Announces Leadership Appointments in the South Market

ATLANTA--(BUSINESS WIRE)--UBS today announced leadership appointments in its South wealth management market, which covers Georgia, Tennessee and Arkansas. John Houlihan has been named Market Executive for the South Market and is responsible for overseeing the market’s Private Wealth Management and Wealth Management businesses. John is based in Atlanta and previously served as Market Director for the firm’s Northeast region. Ian Roth has joined UBS as Senior Market Director, reporting to John. H...
-

Scientist-Inventor Denies Reverse Engineering of Invisibility Cloak

BEDFORD, Mass.--(BUSINESS WIRE)--Recent inquiries linking invisibility cloaks to reverse-engineering have prompted Fractal Antenna Systems’ (“FRACTAL”) CEO Nathan Cohen to issue a statement of record. Electromagnetic cloaking technology was not reverse engineered from extraterrestrial, recovered, or undisclosed technology, nor from any secret government program. While not tied into ETs, the cloaking story itself reads like science or detective fiction but is anchored in fact. Cohen is the inven...
-

Mit Mindbreeze mehr als 8.000 Arbeitsstunden bei Recherche und Datenanalyse eingespart

LINZ--(BUSINESS WIRE)--Mindbreeze, ein weltweit führender Anbieter von KI-basierten Wissensmanagementlösungen unterstützt ein großes US-amerikanisches Unternehmen dabei, Informationen über mehrere Geschäftsbereiche hinweg leichter zugänglich zu machen und die Recherche und Auswertung von Informationen deutlich effizienter zu gestalten. Durch den Einsatz von Mindbreeze InSpire konnte das Unternehmen bereits mehr als 8.000 Arbeitsstunden einsparen – eine geschätzte Zeitersparnis im Wert von mehr...
-

Mindbreeze Helps Large Enterprise Achieve More Than $1 Million in Estimated Time Savings

CHICAGO--(BUSINESS WIRE)--Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that a large U.S. enterprise with research spanning multiple business units has achieved more than $1 million in estimated time savings by using Mindbreeze InSpire to improve research discovery and data mining across the enterprise. The organization manages years of market studies, customer insights, competitive intelligence, product research, and innovation findings acros...
-

Helix Shareholders Approve Combination with Hornbeck Offshore Services

HOUSTON & COVINGTON, La.--(BUSINESS WIRE)--Helix Energy Solutions Group, Inc. (“Helix”) (NYSE: HLX) and Hornbeck Offshore Services, Inc. (“Hornbeck”) announced that Helix’s shareholders have approved the proposals necessary to complete the previously announced all-stock combination of Helix and Hornbeck at a special meeting of Helix’s shareholders held today. “We thank our shareholders for their support of our transaction with Hornbeck,” said Owen Kratz, President and Chief Executive Officer of...
-

Riassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha reso noti i risultati preliminari positivi dalla seconda analisi intermedia (IA2) dello studio clinico di Fase 3 HERIZON-GEA-01 volto a valutare l'efficacia di ZIIHERA® (zanidatamab), in associazione con chemioterapia, con e senza TEVIMBRA® (tislelizumab), come trattamento di prima linea dell'adenocarcinoma gastroesofageo (GEA) HER2-positivi localmente avanzato...
-

MapQuest Surges to No. 1 in the Apple App Store, 30 Years After Inventing Online Mapping

LOS ANGELES--(BUSINESS WIRE)--MapQuest, the original internet mapping service, is the No. 1 Navigation app and the No. 8 overall free app in the U.S. Apple App Store, and the No. 2 overall free app in the Canada Apple App Store, as of 7 p.m. PDT on August 30. It is the highest chart position in the brand's 30-year history. Hundreds of thousands of people have downloaded the MapQuest apps since Thursday, and usage is running roughly 50 times its normal rate. The surge follows MapQuest's decision...
-

Osaic Launches Inaugural Support Staff Symposium

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Osaic, Inc. (“Osaic”), one of the nation’s largest providers of wealth management strategies, today kicked off its Service Excellence Staff Symposium, an event dedicated to bringing together the support professionals who help power Osaic-affiliated advisory firms. Through professional development, peer-to-peer best practice sharing and direct engagement with home office leaders, the symposium is designed to strengthen collaboration, elevate the advisor and cl...